Baumhove Lukas, van Essen Bart J, Dokter Martin M, Zijlstra Sietske N, Deiman Frederik E, Laman Jon D, Lang Chim C, Verstappen Gwenny M P J, van Veldhuisen Dirk J, van der Meer Peter, Bomer Nils, Voors Adriaan A
Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Department of Pathology & Medical Biology, University Medical Center Groningen, Groningen, The Netherlands.
ESC Heart Fail. 2024 Dec;11(6):3530-3538. doi: 10.1002/ehf2.14968. Epub 2024 Jul 19.
Heart failure (HF) is recognized as an inflammatory disease in which cytokines play an important role. In animal HF models, interleukin-17A (IL-17) has been linked to deterioration of cardiac function and fibrosis, whereas knock-out of IL-17 showed beneficial cardiac effects. However, there is limited evidence of IL-17 involvement in patients with HF. This study aims to investigate the clinical characteristics, outcomes, and pathophysiological processes associated with circulating IL-17 concentrations in patients with HF.
IL-17 was measured by ELISA in 2082 patients diagnosed with HF along with 363 circulating proteins using proximity extension assay technology for differential expression and pathway analysis. Data were validated in an independent cohort of 1737 patients with HF. Patients with elevated IL-17 concentrations had more severe HF, as reflected by more frequent current or previous hospitalizations for HF, higher New York Heart Association functional class (NYHA) and higher levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP). High IL-17 concentrations were independently associated with an increased risk of hospitalization for HF and mortality. In both cohorts, the most strongly up-regulated proteins in patients with high IL-17 were fibroblast growth factor 21 (FGF-21), interleukin-6 (IL-6), C-X-C motif chemokine ligand 13 (CXCL13), tumour necrosis factor receptor superfamily member 6B (TNFRSF6B) and interleukin-1 receptor antagonist (IL-1RA). Pathway over-representation analysis showed increased activity of pathways related to lymphocyte-mediated immunity, leukocyte activation and regulation of the immune response.
In patients with HF, elevated IL-17 concentrations indicate more severe HF and increased activity of inflammatory processes known to be involved in the pathophysiology of HF. IL-17 might hold potential for identifying and targeting inflammation in HF.
心力衰竭(HF)被认为是一种炎症性疾病,细胞因子在其中发挥重要作用。在动物HF模型中,白细胞介素-17A(IL-17)与心功能恶化和纤维化有关,而敲除IL-17则显示出对心脏有益的作用。然而,关于IL-17参与HF患者发病过程的证据有限。本研究旨在调查HF患者循环IL-17浓度相关的临床特征、预后及病理生理过程。
采用酶联免疫吸附测定法(ELISA)对2082例诊断为HF的患者进行IL-17检测,并使用邻位延伸分析技术检测363种循环蛋白,以进行差异表达和通路分析。数据在1737例HF患者的独立队列中得到验证。IL-17浓度升高的患者HF病情更严重,表现为当前或既往HF住院频率更高、纽约心脏协会功能分级(NYHA)更高以及N末端B型利钠肽原(NT-proBNP)水平更高。高IL-17浓度与HF住院风险和死亡率增加独立相关。在两个队列中,IL-17浓度高的患者中上调最明显的蛋白是成纤维细胞生长因子21(FGF-21)、白细胞介素-6(IL-6)、C-X-C基序趋化因子配体13(CXCL13)、肿瘤坏死因子受体超家族成员6B(TNFRSF6B)和白细胞介素-1受体拮抗剂(IL-1RA)。通路过度表达分析显示与淋巴细胞介导的免疫、白细胞活化和免疫反应调节相关的通路活性增加。
在HF患者中,IL-17浓度升高表明HF病情更严重,且已知参与HF病理生理过程的炎症过程活性增加。IL-17可能在识别和靶向HF炎症方面具有潜力。